Theolytics secures funds to advance oncolytic adenovirus therapy
18 Apr 2024
Phase 1License out/in
Preview
Source: Pharmaceutical Technology
A Phase I trial will assess THEO-260 for platinum-resistant ovarian cancer patients. Credit: Jo Panuwat D / Shutterstock.com.
UK-based biotechnology company Theolytics has concluded a funding round securing a total of £19m ($24.5m) to advance the development of its lead oncolytic adenovirus therapy, THEO-260.
Sound Bioventures joined as a new investor of Theolytics, alongside an international consortium of existing backers including M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford.
The funding will support the commencement of a Phase I clinical trial of THEO-260 to treat platinum-resistant ovarian cancer.
Beginning this year, the trial will seek to validate the drug’s safety and efficacy.
See Also:
“Lack of harmonisation in Europe” hindering gene therapy growth
Preview
Source: Pharmaceutical Technology
OncoX inks licensing deal worth over $26m for NSCLC therapy
Preview
Source: Pharmaceutical Technology
The trials will explore administration to participants via intravenous or intraperitoneal routes.
Sound Bioventures principal Thomas Tan will join the board of directors of Theolytics
Theolytics is also advancing its preclinical pipeline with novel candidates for colorectal cancer and haematological malignancies.
Theolytics CEO Charlotte Casebourne Stock stated: “Our lead asset THEO-260 will be entering the clinic this year, and at this key juncture we are pleased to complete this significant financing and welcome Sound Bioventures as a new investor.
“Sound Bioventures’ extensive oncology experience, network, operational expertise and collaborative approach will bring important benefits to Theolytics and I am delighted to welcome Thomas Tan to our board.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.